For some, artificial tears may not be enough

Xiidra® can help disrupt the chronic
inflammatory cycle of dry eye disease1-5*

Explore how Xiidra can deliver lasting symptom relief in
as early as 2 weeks.
1†


TAKE A LOOK AT THE DATA HELP YOUR PATIENTS SAVE  >

Xiidra reduced symptoms of eye dryness (based on EDS) at 2 weeks in 2 out of 4 studies, with improvements observed at 6 and 12 weeks in all 4 studies.1

Xiidra Ken Jeong hero image

For some, artificial tears may not be enough

Xiidra® can help disrupt the chronic
inflammatory cycle of dry eye disease1-5*

Explore how Xiidra can deliver lasting symptom relief in as early as 2 weeks.1†

Xiidra reduced symptoms of eye dryness (based on EDS) at 2 weeks in 2 out of 4 studies, with improvements observed at 6 and 12 weeks in all 4 studies.1

FOOTNOTES

*Xiidra blocks LFA-1 on T cells from binding with ICAM-1 that may be overexpressed on the ocular surface in dry eye disease and may prevent formation of an immunologic synapse which, based on in vitro studies, may inhibit T-cell activation, migration of activated T cells to the ocular surface, and reduce cytokine release. The exact mechanism of action of Xiidra in dry eye disease is not known.1,2,5

Your patient’s eyes deserve a change

Consider prescribing Xiidra, a first-in-class Rx therapy indicated for the treatment of the signs and symptoms of dry eye disease.1,6‡

Xiidra is an LFA-1 antagonist for the treatment of dry eye disease.1

Lasting symptom relief in 2 weeks icon

Potential Lasting symptom relief that can start in as early as 2 weeks

Xiidra reduced symptoms of eye dryness (based on EDS) at 2 weeks in 2 out of 4 studies, with improvements observed at 6 and 12 weeks in all 4 studies.1

Address the signs of dry eye disease icon

Help Address the signs of dry eye disease

In 3 out of 4 studies, Xiidra showed notable improvements in signs (based on ICSS) of dry eye disease.1

Safety data in clinical trials icon

Safety data in clinical trials1

The adverse reactions of Xiidra were studied across 5 clinical trials.§

Access for your patients icon

access for your patients

Significantly broader coverage for your Medicare patients: Xiidra is now covered for nearly 3 out of 4 Medicare Part D patients (approximately 70% as of 7/1/22).7

Xiidra has comparable or better coverage to Restasis for 88% of commercially insured patients.

Based on Commercial Formulary Access in National and Regional Accounts on July 12, 2022.

The safety and efficacy of Xiidra were assessed in four 12-week, randomized, multicenter, double-masked, vehicle-controlled studies (N=2133). Patients were dosed twice daily. The mean age was 59 years (range, 19-97 years). The majority of patients were female (76%). Use of artificial tears was not allowed during the studies. The study end points included assessment of signs (based on Inferior fluorescein Corneal Staining Score [ICSS] on a scale of 0 to 4) and symptoms (based on patient-reported Eye Dryness Score [EDS] on a visual analogue scale of 0 to 100). Effects on symptoms of dry eye disease: a larger reduction in EDS favoring Xiidra was observed in all studies at day 42 and day 84. Xiidra reduced symptoms of eye dryness at 2 weeks (based on EDS) compared to vehicle in 2 out of 4 clinical trials. Effects on signs of dry eye disease: at day 84, a larger reduction in ICSS favoring Xiidra was observed in 3 out of the 4 studies.1

§In 5 clinical studies of dry eye disease with lifitegrast ophthalmic solution, 1401 patients received at least 1 dose of lifitegrast (1287 of whom received Xiidra). The majority of patients (84%) had up to 3 months of treatment exposure. One hundred-seventy patients were exposed to Xiidra for approximately 12 months. The most common adverse reactions (reported in 5-25% of patients) were instillation-site irritation, dysgeusia, and reduced visual acuity.1

Based on Commercial Formulary Access in National and Regional Accounts on January 18, 2022.

labtech image

Thought leader perspectives

Dr. Hauser

Approaching DED in Presurgical Patients

Richard L. Lindstrom, MD
Founder and Attending Surgeon Emeritus at Minnesota Eye Consultants
Chief Medical Office and Board Member at TLC Laser Eye Centers
Dr. Lindstrom is a paid consultant for Novartis Pharmaceuticals Corporation, the maker of Xiidra.

Discover his preferred treatment and management plan for DED in patients who are presenting for surgery, from Dr. Richard Lindstrom, Founder and Attending Surgeon Emeritus at Minnesota Eye Consultants, Chief Medical Officer and Board Member at TLC Laser Eye Centers, Senior Lecturer and Trustee Emeritus of the Foundation at the University of Minnesota and Visiting Professor at the UC Irvine Gavin Herbert Eye Institute. Dr. Lindstrom is a paid consultant for Novartis.

Dr. Hauser

Richard L. Lindstrom, MD
Founder and Attending Surgeon Emeritus at Minnesota Eye Consultants
Chief Medical Office and Board Member at TLC Laser Eye Centers
Dr. Lindstrom is a paid consultant for Novartis Pharmaceuticals Corporation, the maker of Xiidra.

See his strategy
labtech

XIIDRA patient case
studies

Dr. Hauser

Patient case study: Melanie

Melanie was a long-time user of artificial tears, but that brought her temporary relief. Read her clinical story, including how her symptoms improved after starting treatment with Xiidra.

Melanie was compensated for her time.

 

Ar’Tee profile

Patient case study: Ar’Tee

Ar’Tee believed his dry eye symptoms were new, but then learned there may be something more. Get the clinical details on Ar’Tee’s case, as well as what happened when he started treatment with Xiidra.

Ar’Tee was compensated for his time.

 


Watch the Video

Xiidra is a nonsteroid therapy specifically developed to treat dry eye disease1,9

See the science behind Xiidra, which targets a key part of an inflammatory cascade and can help disrupt the inflammatory cycle in dry eye disease.1,2,5,10,||


Watch the Video

||Xiidra is an LFA-1 antagonist for the treatment of dry eye disease. The exact mechanism of action of lifitegrast in DED is not known.1

Indication

Xiidra® (lifitegrast ophthalmic solution) 5% is indicated for the treatment of signs and symptoms of dry eye disease (DED).

Important Safety Information

  • Xiidra is contraindicated in patients with known hypersensitivity to lifitegrast or to any of the other ingredients.
  • In clinical trials, the most common adverse reactions reported in 5-25% of patients were instillation site irritation, dysgeusia and reduced visual acuity. Other adverse reactions reported in 1% to 5% of the patients were blurred vision, conjunctival hyperemia, eye irritation, headache, increased lacrimation, eye discharge, eye discomfort, eye pruritus and sinusitis.
  • To avoid the potential for eye injury or contamination of the solution, patients should not touch the tip of the single-use container to their eye or to any surface.
  • Contact lenses should be removed prior to the administration of Xiidra and may be reinserted 15 minutes following administration.
  • Safety and efficacy in pediatric patients below the age of 17 years have not been established.

Click here for Full Prescribing Information.

INDICATION AND IMPORTANT SAFETY INFORMATION

Indication

Xiidra® (lifitegrast ophthalmic solution) 5% is indicated for the treatment of signs and symptoms of dry eye disease (DED).

Important Safety Information

  • Xiidra is contraindicated in patients with known hypersensitivity to lifitegrast or to any of the other ingredients.
  • In clinical trials, the most common adverse reactions reported in 5-25% of patients were instillation site irritation, dysgeusia and reduced visual acuity. Other adverse reactions reported in 1% to 5% of the patients were blurred vision, conjunctival hyperemia, eye irritation, headache, increased lacrimation, eye discharge, eye discomfort, eye pruritus and sinusitis.
  • To avoid the potential for eye injury or contamination of the solution, patients should not touch the tip of the single-use container to their eye or to any surface.
  • Contact lenses should be removed prior to the administration of Xiidra and may be reinserted 15 minutes following administration.
  • Safety and efficacy in pediatric patients below the age of 17 years have not been established.

Click here for Full Prescribing Information.